1,4-二丁基-2-硝基-苯 | 78210-22-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1,4-二丁基-2-硝基-苯
• 英文名称: 1,4-dibutyl-2-nitro-benzene
• 英文别名: 1,4-Dibutyl-2-nitro-benzol；1,4-Dibutyl-2-nitrobenzene
• CAS: 78210-22-7
• 化学式: C₁₄H₂₁NO₂
• 分子量: 235.326
• InChiKey: ARKUOKKZBGHCTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,4-二丁基-2-硝基-苯 在 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 以11.8 g的产率得到2,5-二丁基苯胺
  参考文献：
  名称：

  ＯＬＥＤ素子形成用組成物及びＯＬＥＤ素子

  摘要：

  【问题】提供效率高且溶解性好的发光材料。【解决方法】具有芘骨架的芳香族胺衍生物，例如由下述化合物1表示的芳香族胺衍生物。含有上述芳香族胺衍生物的有机电致发光元件用发光材料。【选定图】图1

  公开号：

  JP2021075493A
• 作为产物：
  描述：

  1,4-二-N-丁基苯 在 硫酸 、 硝酸 作用下， 以 丙酮 为溶剂， 反应 1.33h， 以18 g的产率得到1,4-二丁基-2-硝基-苯
  参考文献：
  名称：

  ＯＬＥＤ素子形成用組成物及びＯＬＥＤ素子

  摘要：

  【问题】提供效率高且溶解性好的发光材料。【解决方法】具有芘骨架的芳香族胺衍生物，例如由下述化合物1表示的芳香族胺衍生物。含有上述芳香族胺衍生物的有机电致发光元件用发光材料。【选定图】图1

  公开号：

  JP2021075493A

文献信息

• ＯＬＥＤ素子形成用組成物及びＯＬＥＤ素子
  申请人：三菱ケミカル株式会社

  公开号：JP2021075493A

  公开（公告）日：2021-05-20

  【課題】素子の効率が十分に高く、溶解性が高い発光材料の提供。【解決手段】ピレン骨格を有する芳香族アミン誘導体であって、例えば下記化合物１で表される芳香族アミン誘導体。前記芳香族アミン誘導体を含有する有機電界発光素子用発光材料。【選択図】図１

  【问题】提供效率高且溶解性好的发光材料。【解决方法】具有芘骨架的芳香族胺衍生物，例如由下述化合物1表示的芳香族胺衍生物。含有上述芳香族胺衍生物的有机电致发光元件用发光材料。【选定图】图1
• Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
  申请人：——

  公开号：US20030040625A1

  公开（公告）日：2003-02-27

  This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstitutedpropanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.

  本发明提供了一类治疗化合物和方法，用于治疗患有生理紊乱的哺乳动物，例如经常出现的一种先天性高血压，这种生理紊乱与镁与细胞质膜结合力下降密切相关。这些方法包括向需要这种治疗的哺乳动物施用选自一系列二取代反式、反式 1，3-丁二烯、1，3-二取代全氢丁二烯、1，2-二取代反式乙烯和 1，2-二取代乙烷和二取代丙烷的化合物，其中每种化合物都共同体现了这些化合物的生物活性所必需的独特结构特征。本发明还提供了采用这些新型化合物的药物制剂。
• ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES
  申请人：Magnesium Diagnostics, Inc.

  公开号：EP1355638B1

  公开（公告）日：2006-05-03
• Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological atates
  申请人：Clifton Ibert

  公开号：US20070010535A1

  公开（公告）日：2007-01-11

  This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.
• Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
  申请人：Wells Clifton Ibert

  公开号：US20070197659A1

  公开（公告）日：2007-08-23

  This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.